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Introduction
Congenital hypothyroidism (CH), the commonest neonatal endocrine disorder, is caused by either 
maldevelopment of  the gland (dysgenesis) or failure of  hormone biosynthesis in a structurally intact 
gland (dyshormonogenesis). As thyroid hormone is indispensable for neurological development, 
growth, and metabolic homeostasis in childhood, delayed diagnosis and treatment of  CH results in 
profound neurodevelopmental and growth retardation. Accordingly, screening programs operate in 
most countries to facilitate prompt neonatal diagnosis (1).
Defects in genes mediating thyroid hormone biosynthesis result in dyshormonogenic congenital 
hypothyroidism (CH). Here, we report homozygous truncating mutations in SLC26A7 in 6 unrelated 
families with goitrous CH and show that goitrous hypothyroidism also occurs in Slc26a7-null mice. 
In both species, the gene is expressed predominantly in the thyroid gland, and loss of function is 
associated with impaired availability of iodine for thyroid hormone synthesis, partially corrected in 
mice by iodine supplementation. SLC26A7 is a member of the same transporter family as SLC26A4 
(pendrin), an anion exchanger with affinity for iodide and chloride (among others), whose gene 
mutations cause congenital deafness and dyshormonogenic goiter. However, in contrast to pendrin, 
SLC26A7 does not mediate cellular iodide efflux and hearing in affected individuals is normal. We 
delineate a hitherto unrecognized role for SLC26A7 in thyroid hormone biosynthesis, for which the 
mechanism remains unclear.
2insight.jci.org   https://doi.org/10.1172/jci.insight.99631
R E S E A R C H  A R T I C L E
Recent reports indicate that CH occurs primarily in association with a eutopic, normal-sized thyroid 
gland, suggesting that dyshormonogenic etiologies may be more important than previously anticipated 
(2). Thyroid hormonogenesis requires sufficient iodide substrate, in addition to an intact molecular path-
way including enzymes, transporter molecules, and thyroglobulin (TG). Active uptake of  iodide across 
the thyrocyte basolateral membrane is mediated by the sodium-iodide symporter (NIS). Iodide is then 
transported across the apical membrane, facilitated, at least in part, by pendrin, acting as a chloride-io-
dide exchanger. Iodide is then oxidized and incorporated into tyrosyl residues of  TG. Such organification 
of  iodide is catalyzed by thyroid peroxidase (TPO) and requires H2O2 generated by dual oxidase type 2 
(DUOX2) and its accessory protein DUOXA2. Unused iodotyrosines are subsequently deiodinated by 
iodotyrosine dehalogenase (IYD) enabling recycling of  intrathyroidal iodide (Figure 1). Mutations in 
known thyroid biosynthetic pathway genes are identified frequently in dyshormonogenic CH, with patient 
phenotypes validating the importance of  these proteins in thyroid hormonogenesis (1). We hypothesized 
that genetic analyses of  cases lacking pathogenic mutations in known genes might identify novel etiologies 
of  dyshormonogenesis. Here, in kindreds lacking mutations in known causative genes, we describe human 
cases with goitrous, dyshormonogenic CH due to homozygous mutations in SLC26A7, an anion trans-
porter, previously shown to function as a chloride-bicarbonate exchanger or chloride channel, mediating 
murine renal bicarbonate resorption and gastric acid secretion (3). Additionally, we delineate a homolo-
gous, goitrous hypothyroid phenotype in Slc26a7-null mice.
Results
Clinical cases. Six families harboring SLC26A7 mutations were studied. Families A, B, and C were consan-
guineous and of  Pakistani (A and B), or Turkish (C) origin. Families D, E, and F were Finnish non-con-
sanguineous kindreds. All children were found to have CH by neonatal screening except for patients of  
family C, who presented with symptomatic hypothyroidism at 3 weeks of  age, since CH screening was not 
available at the site of  their birth. All 13 affected individuals had moderate to severe primary CH as defined 
by European Society for Paediatric Endocrinology (ESPE) criteria (4), with goiter in 8 cases. Less marked 
neonatal thyroid-stimulating hormone (TSH) elevation in AII.iv and AII.v born at 33 weeks, may reflect 
immaturity of  their hypothalamic-pituitary-thyroid axes (Figure 2A) since withdrawal of  levothyroxine 
Figure 1. Thyroid hormone biosynthesis pathway. Schematic depicting the thyroid follicular cell and key components of the thyroid hormone biosynthesis 
pathway. The major steps in iodide metabolism (uptake, efflux, organification, and recycling) are shown. In murine thyroid, Slc26a7 localizes intracellularly and 
to the basal membrane; given its known function as a chloride-bicarbonate transporter in other cell types, Slc26a7 may alter intracellular pH, thereby altering 
iodide uptake or iodide organification as we have observed in murine or human contexts, respectively. DIT, diiodothyronine; MIT, monoiodothyronine.
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treatment in AII.v age 9.8 years suggested permanent hypothyroidism: high TSH of  142 mU/l, low free 
thyroxine (FT4) <0.3 ng/dl (<3.9 pmol/l), and free triiodothyronine (FT3) of  0.33 ng/dl (5.0 pmol/l).
AII.i was noted clinically to have a moderately large goiter (age 5 years), which persisted throughout 
childhood. Ultrasonography (age 10 years), showed an enlarged, heterogeneous, hypervascular thyroid, with 
Figure 2. Clinical genotype and phenotype data for kindreds harboring SLC26A7 mutations, and functional characterization of wild-type and mutant SLC26A7. 
(A) Pedigrees of 6 kindreds illustrating cases with congenital hypothyroidism (CH) and unaffected relatives for whom genetic data were available. Thyroid hor-
mone measurements refer to venous measurements made at diagnosis of CH or following genetic evaluation. Reference ranges: AII.i, iii, iv, v thyroid-stimulating 
hormone (TSH) 0.9–3.5 mU/l, free thyroxine (FT4) 1.1–1.8 ng/dl; AII.ii TSH 0.6–4.8 mU/l, FT4 0.76–1.5 ng/dl; AII.vi. vii, viii, ix TSH 0.4–3.5 mU/l, FT4 0.83–1.69 ng/
dl; BII.i TSH 0.7–5.3 mU/l, FT4 1.1–1.8 ng/dl; CII.i TSH 0.6–4.8 mU/l, FT4 0.8–1.5 ng/dl; CII.ii TSH 0.4–3.5 mU/l, FT4 0.8–1.9 ng/dl; DII.i, ii, EII.i, ii, FII.i, ii TSH 0.35–40 
mU/l, FT4 0.7–1.5 ng/dl. Double horizontal lines indicate consanguinity. FT4: multiply by 12.87 to convert to pmol/l. (B) Quantitative RT-PCR analysis of SLC26A7 
mRNA expression in a human tissue library relative to cyclophilin; horizontal bars denote mean and vertical bars standard error of the mean. (C) Homology model-
ing predicting the protein consequences of the SLC26A7 p.F631Lfs*8 mutation. The deleted protein region is shown in red. (D) HEK293 cells transfected with GFP-
tagged wild-type and F631Lfs*8 SLC26A7 demonstrate localization of wild-type protein to the plasma membrane, whereas the mutant remains intracellular (total 
original magnification, ×63). (E) Box-and-whisker plots for time-dependent iodide efflux from HEK293 cells cotransfected with NIS and pCDNA (white), pendrin 
(gray), or SLC26A7 (stippled black); n = 5 experiments. Boxes extend from the 25th to 75th percentiles, the horizontal line represents the median, and the vertical 
bars represent the minimum and maximum values.
4insight.jci.org   https://doi.org/10.1172/jci.insight.99631
R E S E A R C H  A R T I C L E
numerous focal cysts; at age 14.5 years thyroid volume measured 68 ml. AII.iii developed goiter at age 3.6 
years, with a large goiter evident clinically (volume 91 ml) at age 11 years. Due to poor compliance with 
thyroxine therapy, TSH levels were frequently elevated in both children. Small goiters were evident clinically 
in AII.iv and AII.v (age 1 month), with raised TSH levels (11 and 37 mU/l, respectively) and increased thy-
roid volumes (24.4 ml and 44.4 ml on ultrasound, respectively) at 9.8 years of  age. A small goiter was noted 
clinically following thyroxine withdrawal in BII.i at age 3 years and in CII.i at age 5.7 years, with progressive 
enlargement in the latter. FII.i and DII.ii exhibited a large goiter at birth that persisted in FII.i but resolved in 
DII.ii (ultrasound dimensions at birth: FII.i, right lobe anterior-posterior diameter 31 mm, left lobe 27 mm; 
DII.ii, right thickness 16 mm, left 14 mm). Although the mother of  FII.i had autoimmune hypothyroidism, 
she was adequately replaced with levothyroxine during pregnancy. CII.ii, FII.ii, DII.i, and the siblings in 
family E did not exhibit goiter.
Perchlorate discharge tests were performed in 4 cases following cessation of  levothyroxine treatment for 3 
to 4 weeks, and showed partial iodide organification defects (PIODs). The mean perchlorate-induced iodide 
discharge was 35%, range 14.5%–47% (normal <10%, PIOD 10%–79%), with elevated or high-normal early 
(2 hour) thyroidal radioiodine uptake (mean 35%, range 20%–50%, reference range [RR] 5%–25%). Con-
current biochemical measurements showed elevated TG and elevated or high-normal FT3 levels (Table 1).
Genetic studies. Whole exome sequencing (WES) in kindreds A, D, and E and subsequent Sanger 
sequencing in kindreds B, C, and D identified biallelic truncating mutations in SLC26A7 in all affected 
individuals (c.679C>T, p.R227* families A, B, and C; c.1893delT, p.F631Lfs*8 families D, E, and F). 
All affected individuals were homozygous for the mutations (Figure 2A), which were rare with minor 
allele frequencies 0.00001653 (p.R227*) and 0.0002974 (p.F631Lfs*8), with no reported homozygous 
cases in the Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.org, accessed October 
2017). There are also no biallelic truncating variants (nonsense or frameshift) in SLC26A7 in the ExAC 
database, suggesting this type of  mutational event is exceptionally rare in the general population. Het-
erozygous carriers of  SLC26A7 mutations were euthyroid with the exception of  DI.i, age 48 years, who 
exhibited subclinical hypothyroidism and F1.i who at age 29 years was diagnosed with autoimmune 
hypothyroidism (Supplemental Tables 1 and 2; supplemental material available online with this article; 
https://doi.org/10.1172/jci.insight.99631DS1).
SLC26A7 expression studies and functional characterization. Expression profiling of  different human tissues 
showed strong predominance of  the SLC26A7 transcript in thyroid, suggesting a physiological role (Figure 
2B). This is corroborated in the Genotype Tissue Expression portal, (https://www.gtexportal.org/home/
gene/SLC26A7), with SLC26A7 demonstrating a clear overexpression in thyroid tissue. Differential splicing 
at the human SLC26A7 locus generates 2 different full-length protein isoforms (variant 1, 656 amino acids, 
NP_439897; variant 2, 663 amino acids, NP_599028). Isoform-specific quantitative reverse transcriptase 
PCR (qPCR) showed minimal thyroidal expression of  variant 2 (data not shown), so functional studies were 
undertaken in a variant 1 background.
Table 1. Serum biochemistry, thyroid radioiodine uptake, and perchlorate discharge test results in cases with homozygous SLC26A7 
mutations
Case Age (years) TG (μg/l) TSH (mU/l) FT4 (ng/dl)A FT3 (ng/dl)B % I– uptake 5%–25% (2 hr) Perchlorate discharge (%)
AII.i 12.7 358.5 
(1–35)
22.6 
(0.6-4.8)
0.63 
(0.76-1.49)
0.53 
(0.23-0.55)
20 38.5
AII.iii 9.3 386 
(1–35)
15.9 
(0.4–3.5)
0.89 
(0.83–1.69)
0.61 
(0.23–0.55)
36 14.5
BII.i 3 NA 131 
(0.4–3.5)
<0.30 
(0.83–1.69)
NA NA 47C
CII.i 5.7 320 
(1.6–60)
7.6 
(0.35–4.9)
1.22 
(0.7–1.48)
0.52 
(0.17–0.37)
50 39
Serum biochemistry, thyroid radioiodine (I) uptake, and perchlorate discharge test results in cases with homozygous SLC26A7 mutations. Levothyroxine 
was omitted for 3 weeks prior to evaluation. Discharge of 10%–79% following perchlorate was defined as a partial iodide organification defect. AMultiply 
by 12.87 to convert FT4 to pmol/l. BMultiply by 15.4 to convert FT3 to pmol/l. CBased on 15% thyroidal uptake at 30 minutes. FT3, free triiodothyronine; 
FT4, free thyroxine; TG, thyroglobulin; TSH, thyroid-stimulating hormone. Numbers in parentheses indicate the reference ranges. Bold numbers are values 
outside the reference range.
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SLC26A7 c.679C>T terminates its mRNA transcript very prematurely (ENST00000276609.7, R227*; 
1,257 nt before the last exon junction), strongly predicting its nonsense-mediated decay (5), but undetectable 
SLC26A7 mRNA expression in peripheral blood mononuclear cells (PBMCs; see Figure 2B) precluded val-
idation using blood samples. SLC26A7 c.1893delT is predicted to produce a truncated protein more distally 
(p.F631Lfs*8). Homology modeling suggested destabilization of  its carboxyterminal sulfate transporter and 
antisigma factor antagonist (STAS) domain, which is required for membrane localization and exchanger 
function (6) (Figure 2C). Consistent with this, wild-type GFP-tagged SLC26A7 localized to the membrane 
in transfected cells, whereas the p.F631Lfs*8-SLC26A7 mutant remained intracellular (Figure 2D).
As SLC26A7 is homologous to pendrin (SLC26A4) and humans homozygous for SLC26A7 mutations 
exhibit impaired iodide organification, we hypothesized that SLC26A7 might mediate apical iodide trans-
port in the thyrocyte. However, in contrast to increased iodine efflux from cells expressing pendrin, radioio-
dine loss from SLC26A7-expressing cells was not enhanced, being comparable to control, mock-transfected 
cells (Figure 2E). Furthermore, in contrast to sensorineural deafness in pendrin deficiency, hearing in our 
patients was normal.
Dyshormonogenic hypothyroidism in Slc26a7-null mice. Slc26a7-null mice exhibit perturbed acid-base 
homeostasis, with distal renal tubular acidosis and impaired gastric acid production (3). Accordingly, 
we investigated acid-base status in our patients, but all individuals homozygous for SLC26A7 mutations 
showed normal serum electrolytes and renal function (Supplemental Table 3), with no clinical evidence of  
achlorhydria. Recent data also support a role for rodent Slc26a7 in dental enamel formation (7); however, 
our patients did not exhibit abnormal dentition.
Having documented hypothyroidism in humans with defective SLC26A7, we evaluated the Slc26a7-
null mice, whose thyroid status had not been previously investigated. Slc26a7-null male mice showed hypo-
thyroidism, with low serum T4 levels when first tested at day 14 postpartum (P14) and significantly ele-
vated serum TSH, and low T4 and T3 levels thereafter (Figure 3A). Hypothyroidism was recapitulated in 
both sexes; furthermore, there was no difference in thyroid status between heterozygous mice and wild-type 
animals (Supplemental Figure 1, A and B). Similar to human thyroid, Slc26a7 mRNA is predominantly 
expressed in murine thyroid (Figure 3B). Goiter was evident from P14 onwards, with 1.7-fold increased 
thyroid weight in homozygous compared with wild-type animals and 21.5-fold greater at P90. Thyroid 
histology from homozygous Slc26a7-null mice showed enlarged follicles with excess colloid lined by normal 
or tall follicular epithelium (Figure 3, C and D).
We found that available anti-SLC26A7 sera could not reliably localize SLC26A7 protein in human or 
murine thyroid. Accordingly, we undertook thyroid immunohistochemistry in a different transgenic mouse 
line expressing FLAG-epitope-tagged Slc26a7 (architecture of  modified gene locus and genotype data sum-
marized in Supplemental Figure 2). Anti-FLAG immunostaining in male Slc26a7-FLAG homozygotes 
showed predominantly intracellular protein, with more marked expression at or immediately adjacent to 
the basal membrane (Figure 3E).
Additional studies in Slc26a7-null mice sought to characterize the nature of  defective thyroid hormone 
biosynthesis. Decreased intrathyroidal concentrations of  both TG-bound and free thyroid hormones in null 
mice suggested defective TG iodination and thyroid hormone biosynthesis rather than impaired secretion 
(Figure 4). In contrast to humans, radioiodine studies in null mice showed reduced tracer uptake with nor-
mal discharge following perchlorate administration (Supplemental Figure 1, C and D). However, studies in 
HEK293 cells transfected with SLC26A7, either alone or coexpressed with SLC5A5 (NIS), did not show 
altered iodide uptake (Supplemental Figure 3A).
Supplementation of  30 μg iodide/day, or 40-fold the minimum required amount (7-fold higher than 
that in regular mouse chow), to Slc26a7-null male mice partially reversed the hypothyroidism, achieving an 
exponential decline in TSH (P < 0.001, 1-way ANOVA) and increase in T3 levels (P < 0.05, 2-way ANOVA) 
not seen in heterozygous controls. After 6 weeks of  treatment, TSH and T3 concentrations in Slc26a7-null 
and euthyroid, heterozygous mice were comparable; however, T4 levels did not change during the treatment. 
In keeping with amelioration of  biochemical hypothyroidism, KI treatment of  Slc26a7-null mice produced 
a significant increase in body weight, consistent with increased growth (P < 0.001, 1-way ANOVA). Serum 
iodide concentrations increased significantly in both heterozygous and Slc26a7-null mice with KI supple-
mentation (P < 0.001, 2-way ANOVA). However, both baseline and post-supplementation serum iodide 
levels were most markedly elevated in null mice (P < 0.005) (Supplemental Figure 3, B–F). This is consistent 
with reduced thyroidal iodide uptake, although impaired renal excretion cannot be excluded.
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Figure 3. Characterization of the thyroid phenotype in Slc26a7-null mice and evaluation of murine thyroidal Slc26a7 expression. (A) Box-and-
whisker plots for log10TSH, T4, and T3 measurements in male wild-type (WT, white), and Slc26a7-null mice (KO, stippled black) at 14, 60, and 90 
days of age; n = 6–12 mice of each genotype. Boxes extend from the 25th to 75th percentiles, the horizontal line represents the median, and the 
vertical bars represent the minimum and maximum values. P values were calculated using an unpaired 2-tailed Student’s t test. ***P < 0.0005. 
(B) Quantitative RT-PCR analysis of Slc26a7 mRNA expression in a murine tissue library relative to cyclophilin. Horizontal bars represent the mean 
and error bars represent the standard error of the mean. (C) Photographic representation of the thyroid gland in a male wild-type and Slc26a7-null 
mouse age 90 days, demonstrating goiter in the Slc26a7-null mouse. Box-and-whisker plots below quantify mean thyroid weight/body weight in 
5 WT (white), 18 heterozygous (Het, gray), and 8 Slc26a7-null male mice (KO, stippled black) at P14. P values were calculated using 1-way ANOVA 
with the Newman-Keuls multiple-comparisons test. **P < 0.005, ***P < 0.0005. (D) Hematoxylin and eosin–stained thyroid sections from a male 
Slc26a7-null (KO) mouse compared with a heterozygous littermate (Het) as control age 60 days. Images are representative of sections reviewed from 
3 separate goitrous mice and demonstrate enlarged, colloid-filled follicles with normal-tall follicular cells. Scale bars: 500 μm (top left) and 100 μm. 
(E) Representative thyroid sections from 2 different Slc26a7-FLAG male mice and a wild-type mouse age 75 days, stained with anti-FLAG antibody or 
preimmune serum (control). Arrows denote intracellular and basolateral localization of SLC26A7. Scale bars: 10 μm. NS, not significant.
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Discussion
Our studies indicate that SLC26A7 is indispensable for thyroid hormone biosynthesis in humans and 
mice. In both species, SLC26A7 is predominantly expressed in the thyroid gland, with disruption of  
its function resulting in goitrous CH. A greater reduction of  T4 than T3, together with a partial iodide 
organification defect in humans with homozygous SLC26A7 defects is consistent with reduced TG 
iodination leading to dyshormonogenesis. Indeed, since the first submission of  this report, biallelic, 
truncating mutations in SLC26A7 were reported in a single Saudi Arabian family with dyshormonoge-
netic CH (8). Due to differing dietary iodine intake, variable TSH levels in utero, genetic background, 
and other unknown factors, variability of  goiter (presence and size) is recognized in dyshormonogenesis 
despite identical genetic basis (9). Slc26a7-null mice exhibit a homologous phenotype of  early postnatal 
hypothyroidism, with enlarged thyroid gland and more severely reduced T4 than T3 in serum and in 
thyroid, both indicating impaired iodine availability for hormone biosynthesis.
Our identification of  SLC26A7 mutations in dyshormonogenic CH widens the known spectrum of human 
disease associated with the 10-member SLC26 anion transporter and channel protein family: SLC26A2 sulfate 
transporter mutations disrupt proteoglycan sulfation resulting in a spectrum of chondrodysplasias; defects in 
SLC26A3, a colonic Cl–/HCO3
– exchanger, cause congenital, chloride-losing diarrhea; SLC26A4 mutations 
causing deficiency in pendrin, an apical iodide transporter in thyroid cells and Cl–/HCO3
– exchanger in the 
cochlear endolymphatic system, result in congenital deafness and dyshormonogenic goiter (10).
Although SLC26A7 shares substantial homology with pendrin, SLC26A7-related CH is clinically dis-
tinct from the phenotype associated with loss of  pendrin function and our data do not support a direct role 
for SLC26A7 in mediating cellular iodide efflux. Indeed, whilst the existence of  additional transporters 
other than pendrin mediating iodide efflux from the thyrocyte are long recognized, recent studies suggest 
that anoctamin-1 may fulfil this function, although the relative physiological roles of  these proteins requires 
further evaluation (11, 12).
SLC26A7 function was previously characterized in rodents, where it maintains acid-base homeostasis 
by facilitating renal bicarbonate resorption via Cl–/HCO3
– exchange at the basolateral membrane of  the 
α-intercalated cells in the outer medullary collecting duct (OMCD) (13). It also localizes to the basolateral 
Figure 4. Intrathyroidal hormone measurements in male Slc26a7-null mice. Box-and-whisker plots for intrathyroidal 
TG-bound and free (F) T4 and T3 levels in male wild-type (WT, white) and homozygous Slc26a7-null mice (KO, stippled 
black) age 90 days. Boxes extend from the 25th to 75th percentiles, the horizontal line represents the median, and the 
vertical bars represent the minimum and maximum values. Measurements were made from 6–10 mice of each genotype. 
P values were calculated using an unpaired 2-tailed Student’s t test. ***P < 0.0005.
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membrane of  gastric parietal cells and may either facilitate HCO3
– efflux or function as a Cl– channel, 
regulating gastric acid secretion (14, 15, 3) in agreement with our localization of  Slc26a7 protein to both 
intracellular and basal membrane compartments in thyroid follicular cells. Additionally, Slc26a7 contrib-
utes to maintenance of  the pH regulatory network during maturation of  murine tooth enamel (7). With 
documented distal renal tubular acidosis and gastric achlorhydria in Slc26a7-null mice, we found no overt 
renal acid-base abnormalities in our homozygous SLC26A7-mutant patients in the healthy state, but cannot 
exclude its role when homeostasis is perturbed, analogous to the renal role of  pendrin during systemic 
metabolic alkalosis (16).
The precise mechanism by which SLC26A7 regulates murine and human thyroid hormone biosynthe-
sis requires further investigation. In humans, defective SLC26A7 results in impaired iodide organification 
with preserved thyroidal iodide uptake; however, in vitro studies did not demonstrate a direct role for 
SLC26A7 in mediating iodide efflux. Slc26a7 expression at the basolateral membrane in murine thyro-
cytes, and impaired iodide uptake with partial reversal of  hypothyroidism after iodide supplementation 
in Slc26a7-null mice, suggest a role for Slc26a7 in thyroidal uptake of  iodide. However, in both mice and 
humans, the sodium-iodide transporter (NIS/SLC5A5) is the major mediator of  thyroidal iodide uptake, 
with loss of  SLC5A5 function resulting in profound CH in both species (17, 18), suggesting a permissive 
rather than direct role for Slc26a7 in facilitating iodide uptake in mice. Furthermore, preserved thyroidal 
iodide uptake in SLC26A7-deficient humans suggests that Slc26a7 transporter function may differ between 
the two species. A precedent for this is provided by the observation that the KCNQ1-KCNE2 potassium 
channel is crucial in facilitating murine NIS activity, whereas biallelic KCNQ1 mutations in humans pre-
dispose to cardiac arrhythmias but not thyroid dysfunction (19, 20).
The role of SLC26A7 as a Cl–/HCO3
– exchanger, controlling acid-base balance in the renal tubule and 
gastric epithelium, may indicate an analogous function in thyroid follicular cells, since optimal ionic milieu 
and pH are known to be critical for enzyme (TPO, DUOX2) and anion exchanger activities during thyroid 
hormone biosynthesis (21). It is therefore possible that SLC26A7 plays a common role in thyroidal Cl–/HCO3
– 
homeostasis in humans and mice, with species differences in thyroid cell electrophysiology mediating divergent 
effects on iodide metabolism, perhaps accounting for the preserved iodide uptake but impaired organification 
we observed in human SLC26A7 deficiency, with reduced iodide uptake and normal organification in Slc26a7-
null mice (Figure 1). Future research aims to map the subcellular location of Slc26a7 in thyrocytes from both 
species more precisely and measure intracellular pH, changes in ionic milieu, and function of proteins mediat-
ing iodide uptake, efflux, and organification in wild-type or mutant-Slc26a7-expressing cells.
We have identified what we believe is a novel genetic cause of dyshormonogenic CH, and delineated a crit-
ical role for SLC26A7 in human and murine thyroid hormone biosynthesis. Although there are notable differ-
ences in the effect of SLC26A7 deficiency in humans and mice, such as thyroidal uptake, perchlorate discharge, 
and the effect on kidneys and teeth, both species manifest congenital goitrous hypothyroidism. Further, irre-
spective of the precise mechanism of SLC26A7 action, in both species thyroid hormone deficiency is caused by 
reduction of iodine availability for hormone synthesis. Both humans and mice have more severe reduction of  
T4 than T3 in thyroid as well as in serum at baseline and this is partially corrected by iodide supplementation 
in the mouse. An increase in the T3 to T4 ratio has been observed in endemic areas of iodine deficiency as well 
as in reduced iodine uptake due to NIS defects (17). It reflects the relative abundance of monoiodotyrosine due 
to poor iodination of TG with the consequent predominant synthesis of T3 rather than T4.
Methods
Case selection. Cases with CH and eutopic gland-in-situ, in whom mutations in known dyshormonogene-
sis-associated genes had been excluded, were recruited.
Genetic studies. WES of  genomic DNA samples was used to identify rare, biallelic variants in genes with 
a likely role in thyroid physiology, which segregated with disease within and across families. The index cas-
es (AII.i, AII.iii) were sequenced under the auspices of  the UK10K project, www.UK10K.org (22). Sanger 
sequencing was used to verify WES findings and to identify additional cases harboring SLC26A7 gene 
mutations (detailed methods are available in the supplemental section). Next-generation sequence data that 
support this study have been deposited in the European Genome-phenome Archive (EGA) under the data 
set accession codes EGAD00001000420 and EGAD00001004293.
In silico modeling. The model for SLC26A7 was generated using the phyre2 (Protein Homology/
AnalogY Recognition Engine 2) web portal, which predicts and analyzes protein structures based on 
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homology/analogy recognition to solved protein crystal structures (23). The figures were generated with 
MacPyMOL Molecular Graphics System, Schrödinger, LLC.
Expression of  SLC26A7. SLC26A7 mRNA expression was measured in human and murine tissue RNA 
libraries using qPCR. The Slc26a7 protein expression pattern was evaluated immunohistochemically in trans-
genic mice expressing FLAG-epitope-tagged Slc26a7 (see Methods section and supplemental appendix).
Cellular localization of  SLC26A7 and iodide transport studies. Expression vectors containing GFP-tagged 
wild-type or mutant SLC26A7 complementary DNAs or wild-type pendrin and SLC26A7 were transfected 
in HEK293 cells (American Type Culture Collection, ATCC), assaying cellular localization or radiolabeled 
iodide uptake and efflux (see Methods section and supplemental appendix).
Characterization of  Slc26a7-null mice. Slc26a7-null mice were generated as previously described (3); 
generation of  transgenic mice expressing FLAG-epitope-tagged Slc26a7 together with their physiologi-
cal, biochemical, and histological characterization is detailed in the supplemental appendix.
Statistics. Unless otherwise stated, in studies in which statistical analyses were performed, P values 
were calculated using an unpaired 2-tailed Student’s t test and error bars represent the standard error of  
the mean. One-way ANOVA with a Newman-Keuls post test was used when performing multiple group 
comparisons, such as during the iodide supplementation study (body weight, TSH, and T4); additionally, a 
linear trend post test was performed in these studies. In the analysis of  T3 and iodide concentrations during 
iodide supplementation, 2-way ANOVA with Bonferroni’s post test was used. In the cellular iodide uptake 
study in HEK293 cells, a 1-way ANOVA with Tukey’s post test was performed. P values less than 0.05 were 
considered significant and the following abbreviations were used: *P < 0.05, **P < 0.005, ***P < 0.0005.
Study approval. All human investigations were part of  an ethically approved protocol (Cambridge South, 
MREC 98/5/24), and/or clinically indicated, being undertaken with informed consent from patients and/
or parents. All murine studies were regulated under the Animals (Scientific Procedures) Act 1986 Amend-
ment Regulations 2012 following ethical review by the University of  Cambridge Animal Welfare and Ethi-
cal Review Body (AWERB) (UK Home Office Licence no. 80/2098) or conducted in accordance to proto-
col 71761 approved by the University of  Chicago Animal Care and Use Committee.
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